Comparative Efficacy of bDMARDs and tsDMARDs for the Treatment of Rheumatoid arthritis: A Systematic Review and Network Meta-Analysis
DOI:
https://doi.org/10.54097/ijbls.v3i1.9623Keywords:
Biologic Disease-modifying Anti-rheumatic Drugs, Network Meta-analysis, Rheumatoid Arthritis, Targeted Synthetic Disease-modifying Anti-rheumatic DrugsAbstract
To compare the relative clinical efficacy of biologic disease-modifying anti-rheumatic drugs (bDMARDs) and targeted synthetic disease-modifying anti-rheumatic drugs (tsDMARDs) (adalimumab, infliximab, certolizumab pegol, golimumab, tocilizumab, sarilumab, tofacitinib, baricitinib, upadacitinib, peficitinib, filgotinib, abatacept, anakinra, rituximab) in patients with rheumatoid arthritis (RA) who had been treated with conventional synthetic disease-modifying anti-rheumatic drugs (csDMARDs) without adequate response by network meta-analysis. The computer comprehensively searched PubMed, Embase, Cochrane Library, Web of Science, China Knowledge Network (CNKI), Chinese Biomedical Literature Database (CBM), Wanfang, and VIP databases for randomized controlled trials (RCTs) of bDMARDs and tsDMARDs in the treatment of RA. The search time limit was set from the establishment of the databases to February 18, 2023. The quality assessment of the included studies was performed using the Cochrane Collaboration’s tool, and the R software (version 4.1.3) calling the gemtc package (version 1.0-1) in conjunction with JAGS software was for data analysis. Efficacy outcomes included American College of Rheumatology 20%, 50%, 70% response (ACR20, ACR50, ACR70). The included 68 RCTs, totaling 32356 patients with RA were analyzed. There were 68, 64 and 63 studies reported the outcomes of ACR20, ACR50, and ACR70 respectively. The result showed that fifteen drugs all had significant difference compared with placebo. According to the SUCRA values, certolizumab pegol had the highest probability of becoming the best intervention in ACR20 and ACR50, and etanercept was ranked first in ACR70, followed by certolizumab pegol. In conclusion, bDMARDs and tsDMARDs were all effective in improving signs and symptoms in RA patients who had been treated with csDMARDs without adequate response. Certolizumab combined with csDMARDs had better performance on efficacy compared with other interventions.
Downloads
References
SMOLEN J S, ALETAHA D, MCINNES I B. Rheumatoid arthritis [J]. Lancet (London, England), 2016, 388(10055): 2023-2038.
CROWSON C S, MATTESON E L, MYASOEDOVA E, et al. The lifetime risk of adult-onset rheumatoid arthritis and other inflammatory autoimmune rheumatic diseases [J]. Arthritis and rheumatism, 2011, 63(3): 633-639.
HOLMQVIST M, LJUNG L, ASKLING J. Mortality following new-onset Rheumatoid Arthritis: has modern Rheumatology had an impact? [J]. Annals of the rheumatic diseases, 2018, 77(1): 85-91.
YANG Q, YANG J, YANG Y, et al. Research Progress on Drug and Surgical Treatment of Rheumatoid Arthritis [J]. Chinese Archives of Traditional Chinese Medicine, 2023, 41(01): 133-136.
SMOLEN J S, LANDEWé R, BIJLSMA J, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2016 update [J]. Annals of the rheumatic diseases, 2017, 76(6): 960-977.
TAYLOR P C. Clinical efficacy of launched JAK inhibitors in rheumatoid arthritis [J]. Rheumatology (Oxford, England), 2019, 58(Supplement_1): i17-i26.
2018 Chinese Guidelines for the Diagnosis and Treatment of Rheumatoid Arthritis Rheumatology Branch of Chinese Medical Association [J]. Clinical Research and Practice, 2018, 3(12): 201.
SMOLEN J S, LANDEWé R B M, BIJLSMA J W J, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 update [J]. Annals of the rheumatic diseases, 2020, 79(6): 685-699.
FRAENKEL L, BATHON J M, ENGLAND B R, et al. 2021 American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis [J]. Arthritis care & research, 2021, 73(7): 924-939.
ARNETT F C, EDWORTHY S M, BLOCH D A, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis [J]. Arthritis and rheumatism, 1988, 31(3): 315-324.
ALETAHA D, NEOGI T, SILMAN A J, et al. 2010 rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative [J]. Annals of the rheumatic diseases, 2010, 69(9): 1580-1588.
WEINBLATT M E, KEYSTONE E C, FURST D E, et al. Adalimumab, a fully human anti-tumor necrosis factor alpha monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: the ARMADA trial [J]. Arthritis and rheumatism, 2003, 48(1): 35-45.
KEYSTONE E C, KAVANAUGH A F, SHARP J T, et al. Radiographic, clinical, and functional outcomes of treatment with adalimumab (a human anti-tumor necrosis factor monoclonal antibody) in patients with active rheumatoid arthritis receiving concomitant methotrexate therapy: a randomized, placebo-controlled, 52-week trial [J]. Arthritis and rheumatism, 2004, 50(5): 1400-1411.
FURST D E, SCHIFF M H, FLEISCHMANN R M, et al. Adalimumab, a fully human anti-tumor necrosis factor-alpha monoclonal antibody, and concomitant standard antirheumatic therapy for the treatment of rheumatoid arthritis: results of STAR (Safety Trial of Adalimumab in Rheumatoid Arthritis) [J]. The Journal of rheumatology, 2003, 30(12): 2563-2571.
CHEN D Y, CHOU S J, HSIEH T Y, et al. Randomized, double-blind, placebo-controlled, comparative study of human anti-TNF antibody adalimumab in combination with methotrexate and methotrexate alone in Taiwanese patients with active rheumatoid arthritis [J]. Journal of the Formosan Medical Association = Taiwan yi zhi, 2009, 108(4): 310-319.
KIM H-Y, LEE S-K, SONG Y W, et al. A randomized, double-blind, placebo-controlled, phase III study of the human anti-tumor necrosis factor antibody adalimumab administered as subcutaneous injections in Korean rheumatoid arthritis patients treated with methotrexate [J]. APLAR Journal of Rheumatology, 2007, 10(1): 9-16.
HUANG F, ZHANG F, BAO C, et al. A multicenter, randomized, double-blind, placebo-controlled clinical study of Adalimumab combined with methotrexate in the treatment of rheumatoid arthritis [J]. Chinese Journal of Internal Medicine, 2009, 48(11): 916-921.
LIPSKY P E, VAN DER HEIJDE D M, ST CLAIR E W, et al. Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group [J]. The New England journal of medicine, 2000, 343(22): 1594-1602.
ABE T, TAKEUCHI T, MIYASAKA N, et al. A multicenter, double-blind, randomized, placebo-controlled trial of infliximab combined with low dose methotrexate in Japanese patients with rheumatoid arthritis [J]. The Journal of rheumatology, 2006, 33(1): 37-44.
KIM J, RYU H, YOO D H, et al. A clinical trial and extension study of infliximab in Korean patients with active rheumatoid arthritis despite methotrexate treatment [J]. Journal of Korean medical science, 2013, 28(12): 1716-1722.
WESTHOVENS R, YOCUM D, HAN J, et al. The safety of infliximab, combined with background treatments, among patients with rheumatoid arthritis and various comorbidities: a large, randomized, placebo-controlled trial [J]. Arthritis and rheumatism, 2006, 54(4): 1075-1086.
ZHANG F C, HOU Y, HUANG F, et al. Infliximab versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a preliminary study from China [J]. APLAR Journal of Rheumatology, 2006, 9(2): 127-130.
GAO G, LI J, XIE H, et al. Recombinant anti-tumor necrosis factor- α Clinical evaluation of human mouse chimeric monoclonal antibody therapy for moderate to severe active rheumatoid arthritis [J]. Journal of Southern Medical University, 2010, 30(4): 724-726.
HUANG F, DENG X, ZHANG J, et al. Randomized double-blind clinical study of infliximab combined with methotrexate in the treatment of rheumatoid arthritis [J]. Chinese Journal of Rheumatology, 2006, 10(9): 522-526.
KEYSTONE E, HEIJDE D, MASON D, JR., et al. Certolizumab pegol plus methotrexate is significantly more effective than placebo plus methotrexate in active rheumatoid arthritis: findings of a fifty-two-week, phase III, multicenter, randomized, double-blind, placebo-controlled, parallel-group study [J]. Arthritis and rheumatism, 2008, 58(11): 3319-3329.
SMOLEN J S, EMERY P, FERRACCIOLI G F, et al. Certolizumab pegol in rheumatoid arthritis patients with low to moderate activity: the CERTAIN double-blind, randomised, placebo-controlled trial [J]. Annals of the rheumatic diseases, 2015, 74(5): 843-850.
CHOY E, MCKENNA F, VENCOVSKY J, et al. Certolizumab pegol plus MTX administered every 4 weeks is effective in patients with RA who are partial responders to MTX [J]. Rheumatology (Oxford, England), 2012, 51(7): 1226-1234.
SMOLEN J, LANDEWé R B, MEASE P, et al. Efficacy and safety of certolizumab pegol plus methotrexate in active rheumatoid arthritis: the RAPID 2 study. A randomised controlled trial [J]. Annals of the rheumatic diseases, 2009, 68(6): 797-804.
YAMAMOTO K, TAKEUCHI T, YAMANAKA H, et al. Efficacy and safety of certolizumab pegol plus methotrexate in Japanese rheumatoid arthritis patients with an inadequate response to methotrexate: the J-RAPID randomized, placebo-controlled trial [J]. Modern rheumatology, 2014, 24(5): 715-724.
SMOLEN J S, BURMESTER G R, COMBE B, et al. Head-to-head comparison of certolizumab pegol versus adalimumab in rheumatoid arthritis: 2-year efficacy and safety results from the randomised EXXELERATE study [J]. Lancet (London, England), 2016, 388(10061): 2763-2774.
KANG Y M, PARK Y E, PARK W, et al. Rapid onset of efficacy predicts response to therapy with certolizumab plus methotrexate in patients with active rheumatoid arthritis [J]. The Korean journal of internal medicine, 2018, 33(6): 1224-1233.
BI L, LI Y, HE L, et al. Efficacy and safety of certolizumab pegol in combination with methotrexate in methotrexate-inadequate responder Chinese patients with active rheumatoid arthritis: 24-week results from a randomised, double-blind, placebo-controlled phase 3 study [J]. Clinical and experimental rheumatology, 2019, 37(2): 227-234.
KAY J, MATTESON E L, DASGUPTA B, et al. Golimumab in patients with active rheumatoid arthritis despite treatment with methotrexate: a randomized, double-blind, placebo-controlled, dose-ranging study [J]. Arthritis and rheumatism, 2008, 58(4): 964-975.
LI Z, ZHANG F, KAY J, et al. Efficacy and safety results from a Phase 3, randomized, placebo-controlled trial of subcutaneous golimumab in Chinese patients with active rheumatoid arthritis despite methotrexate therapy [J]. International journal of rheumatic diseases, 2016, 19(11): 1143-1156.
TANAKA Y, HARIGAI M, TAKEUCHI T, et al. Golimumab in combination with methotrexate in Japanese patients with active rheumatoid arthritis: results of the GO-FORTH study [J]. Annals of the rheumatic diseases, 2012, 71(6): 817-824.
KEYSTONE E C, GENOVESE M C, KLARESKOG L, et al. Golimumab, a human antibody to tumour necrosis factor {alpha} given by monthly subcutaneous injections, in active rheumatoid arthritis despite methotrexate therapy: the GO-FORWARD Study [J]. Annals of the rheumatic diseases, 2009, 68(6): 789-796.
KREMER J, RITCHLIN C, MENDELSOHN A, et al. Golimumab, a new human anti-tumor necrosis factor alpha antibody, administered intravenously in patients with active rheumatoid arthritis: Forty-eight-week efficacy and safety results of a phase III randomized, double-blind, placebo-controlled study [J]. Arthritis and rheumatism, 2010, 62(4): 917-928.
WEINBLATT M E, BINGHAM C O, 3RD, MENDELSOHN A M, et al. Intravenous golimumab is effective in patients with active rheumatoid arthritis despite methotrexate therapy with responses as early as week 2: results of the phase 3, randomised, multicentre, double-blind, placebo-controlled GO-FURTHER trial [J]. Annals of the rheumatic diseases, 2013, 72(3): 381-389.
WEINBLATT M E, KREMER J M, BANKHURST A D, et al. A trial of etanercept, a recombinant tumor necrosis factor receptor: Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate [J]. The New England journal of medicine, 1999, 340(4): 253-259.
CHEN X X, LI Z G, WU H X, et al. A randomized, controlled trial of efficacy and safety of Anbainuo, a bio-similar etanercept, for moderate to severe rheumatoid arthritis inadequately responding to methotrexate [J]. Clinical rheumatology, 2016, 35(9): 2175-2183.
HOBBS K, DEODHAR A, WANG B, et al. Randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of etanercept in patients with moderately active rheumatoid arthritis despite DMARD therapy [J]. Springerplus, 2015, 4: 113.
CHEN S, CHEN S, HUANG F, et al. A randomized, double-blind, multicenter controlled study of etanercept in the treatment of active rheumatoid arthritis patients in China receiving methotrexate treatment [J]. Chinese Journal of Rheumatology, 2010, 14(7): 450-455.
SMOLEN J S, BEAULIEU A, RUBBERT-ROTH A, et al. Effect of interleukin-6 receptor inhibition with tocilizumab in patients with rheumatoid arthritis (OPTION study): a double-blind, placebo-controlled, randomised trial [J]. Lancet (London, England), 2008, 371(9617): 987-997.
MAINI R N, TAYLOR P C, SZECHINSKI J, et al. Double-blind randomized controlled clinical trial of the interleukin-6 receptor antagonist, tocilizumab, in European patients with rheumatoid arthritis who had an incomplete response to methotrexate [J]. Arthritis and rheumatism, 2006, 54(9): 2817-2829.
GENOVESE M C, MCKAY J D, NASONOV E L, et al. Interleukin-6 receptor inhibition with tocilizumab reduces disease activity in rheumatoid arthritis with inadequate response to disease-modifying antirheumatic drugs: the tocilizumab in combination with traditional disease-modifying antirheumatic drug therapy study [J]. Arthritis and rheumatism, 2008, 58(10): 2968-2980.
BAEK H J, LIM M J, PARK W, et al. Efficacy and safety of tocilizumab in Korean patients with active rheumatoid arthritis [J]. The Korean journal of internal medicine, 2019, 34(4): 917-931.
KREMER J M, BLANCO R, BRZOSKO M, et al. Tocilizumab inhibits structural joint damage in rheumatoid arthritis patients with inadequate responses to methotrexate: results from the double-blind treatment phase of a randomized placebo-controlled trial of tocilizumab safety and prevention of structural joint damage at one year [J]. Arthritis and rheumatism, 2011, 63(3): 609-621.
SHI Q, ZHAO Y, BAO C, et al. A multicenter, randomized, double-blind, placebo-controlled clinical study on the treatment of rheumatoid arthritis with Tozumab combined with anti-rheumatic drugs to improve the condition [J]. Chinese Journal of Internal Medicine, 2013, 52(4): 323-329.
GENOVESE M C, FLEISCHMANN R, KIVITZ A J, et al. Sarilumab Plus Methotrexate in Patients with Active Rheumatoid Arthritis and Inadequate Response to Methotrexate: Results of a Phase III Study [J]. Arthritis & rheumatology (Hoboken, NJ), 2015, 67(6): 1424-1437.
HUIZINGA T W, FLEISCHMANN R M, JASSON M, et al. Sarilumab, a fully human monoclonal antibody against IL-6Rα in patients with rheumatoid arthritis and an inadequate response to methotrexate: efficacy and safety results from the randomised SARIL-RA-MOBILITY Part A trial [J]. Annals of the rheumatic diseases, 2014, 73(9): 1626-1634.
TANAKA Y, WADA K, TAKAHASHI Y, et al. Sarilumab plus methotrexate in patients with active rheumatoid arthritis and inadequate response to methotrexate: results of a randomized, placebo-controlled phase III trial in Japan [J]. Arthritis research & therapy, 2019, 21(1): 79.
VAN VOLLENHOVEN R F, FLEISCHMANN R, COHEN S, et al. Tofacitinib or adalimumab versus placebo in rheumatoid arthritis [J]. The New England journal of medicine, 2012, 367(6): 508-519.
FLEISCHMANN R, MYSLER E, HALL S, et al. Efficacy and safety of tofacitinib monotherapy, tofacitinib with methotrexate, and adalimumab with methotrexate in patients with rheumatoid arthritis (ORAL Strategy): a phase 3b/4, double-blind, head-to-head, randomised controlled trial [J]. Lancet (London, England), 2017, 390(10093): 457-468.
VAN DER HEIJDE D, TANAKA Y, FLEISCHMANN R, et al. Tofacitinib (CP-690,550) in patients with rheumatoid arthritis receiving methotrexate: twelve-month data from a twenty-four-month phase III randomized radiographic study [J]. Arthritis and rheumatism, 2013, 65(3): 559-70.
TANAKA Y, SUZUKI M, NAKAMURA H, et al. Phase II study of tofacitinib (CP-690,550) combined with methotrexate in patients with rheumatoid arthritis and an inadequate response to methotrexate [J]. Arthritis care & research, 2011, 63(8): 1150-1158.
TAYLOR P C, KEYSTONE E C, VAN DER HEIJDE D, et al. Baricitinib versus Placebo or Adalimumab in Rheumatoid Arthritis [J]. The New England journal of medicine, 2017, 376(7): 652-662.
TANAKA Y, EMOTO K, CAI Z, et al. Efficacy and Safety of Baricitinib in Japanese Patients with Active Rheumatoid Arthritis Receiving Background Methotrexate Therapy: A 12-week, Double-blind, Randomized Placebo-controlled Study [J]. The Journal of rheumatology, 2016, 43(3): 504-511.
KEYSTONE E C, TAYLOR P C, DRESCHER E, et al. Safety and efficacy of baricitinib at 24 weeks in patients with rheumatoid arthritis who have had an inadequate response to methotrexate [J]. Annals of the rheumatic diseases, 2015, 74(2): 333-340.
DOUGADOS M, VAN DER HEIJDE D, CHEN Y C, et al. Baricitinib in patients with inadequate response or intolerance to conventional synthetic DMARDs: results from the RA-BUILD study [J]. Annals of the rheumatic diseases, 2017, 76(1): 88-95.
FLEISCHMANN R, PANGAN A L, SONG I H, et al. Upadacitinib Versus Placebo or Adalimumab in Patients with Rheumatoid Arthritis and an Inadequate Response to Methotrexate: Results of a Phase III, Double-Blind, Randomized Controlled Trial [J]. Arthritis & rheumatology (Hoboken, NJ), 2019, 71(11): 1788-1800.
BURMESTER G R, KREMER J M, VAN DEN BOSCH F, et al. Safety and efficacy of upadacitinib in patients with rheumatoid arthritis and inadequate response to conventional synthetic disease-modifying anti-rheumatic drugs (SELECT-NEXT): a randomised, double-blind, placebo-controlled phase 3 trial [J]. Lancet (London, England), 2018, 391(10139): 2503-2512.
KAMEDA H, TAKEUCHI T, YAMAOKA K, et al. Efficacy and safety of upadacitinib in Japanese patients with rheumatoid arthritis (SELECT-SUNRISE): a placebo-controlled phase IIb/III study [J]. Rheumatology (Oxford, England), 2020, 59(11): 3303-3313.
ZENG X, ZHAO D, RADOMINSKI S C, et al. Upadacitinib in patients from China, Brazil, and South Korea with rheumatoid arthritis and an inadequate response to conventional therapy [J]. International journal of rheumatic diseases, 2021, 24(12): 1530-1539.
GENOVESE M C, SMOLEN J S, WEINBLATT M E, et al. Efficacy and Safety of ABT-494, a Selective JAK-1 Inhibitor, in a Phase IIb Study in Patients with Rheumatoid Arthritis and an Inadequate Response to Methotrexate [J]. Arthritis & rheumatology (Hoboken, NJ), 2016, 68(12): 2857-2866.
COMBE B, KIVITZ A, TANAKA Y, et al. Filgotinib versus placebo or adalimumab in patients with rheumatoid arthritis and inadequate response to methotrexate: a phase III randomised clinical trial [J]. Annals of the rheumatic diseases, 2021, 80(7): 848-858.
WESTHOVENS R, TAYLOR P C, ALTEN R, et al. Filgotinib (GLPG0634/GS-6034), an oral JAK1 selective inhibitor, is effective in combination with methotrexate (MTX) in patients with active rheumatoid arthritis and insufficient response to MTX: results from a randomised, dose-finding study (DARWIN 1) [J]. Annals of the rheumatic diseases, 2017, 76(6): 998-1008.
TAKEUCHI T, TANAKA Y, TANAKA S, et al. Efficacy and safety of peficitinib (ASP015K) in patients with rheumatoid arthritis and an inadequate response to methotrexate: results of a phase III randomised, double-blind, placebo-controlled trial (RAJ4) in Japan [J]. Annals of the rheumatic diseases, 2019, 78(10): 1305-1319.
KIVITZ A J, GUTIERREZ-UREñA S R, POILEY J, et al. Peficitinib, a JAK Inhibitor, in the Treatment of Moderate-to-Severe Rheumatoid Arthritis in Patients with an Inadequate Response to Methotrexate [J]. Arthritis & rheumatology (Hoboken, NJ), 2017, 69(4): 709-719.
GENOVESE M C, GREENWALD M, CODDING C, et al. Peficitinib, a JAK Inhibitor, in Combination with Limited Conventional Synthetic Disease-Modifying Antirheumatic Drugs in the Treatment of Moderate-to-Severe Rheumatoid Arthritis [J]. Arthritis & rheumatology (Hoboken, NJ), 2017, 69(5): 932-942.
KREMER J M, DOUGADOS M, EMERY P, et al. Treatment of rheumatoid arthritis with the selective costimulation modulator abatacept: twelve-month results of a phase iib, double-blind, randomized, placebo-controlled trial [J]. Arthritis and rheumatism, 2005, 52(8): 2263-2271.
SCHIFF M, KEISERMAN M, CODDING C, et al. Efficacy and safety of abatacept or infliximab vs placebo in ATTEST: a phase III, multi-centre, randomised, double-blind, placebo-controlled study in patients with rheumatoid arthritis and an inadequate response to methotrexate [J]. Annals of the rheumatic diseases, 2008, 67(8): 1096-1103.
WEINBLATT M E, SCHIFF M, VALENTE R, et al. Head-to-head comparison of subcutaneous abatacept versus adalimumab for rheumatoid arthritis: findings of a phase IIIb, multinational, prospective, randomized study [J]. Arthritis and rheumatism, 2013, 65(1): 28-38.
KREMER J M, GENANT H K, MORELAND L W, et al. Effects of abatacept in patients with methotrexate-resistant active rheumatoid arthritis: a randomized trial [J]. Annals of internal medicine, 2006, 144(12): 865-876.
TAKEUCHI T, MATSUBARA T, NITOBE T, et al. Phase II dose-response study of abatacept in Japanese patients with active rheumatoid arthritis with an inadequate response to methotrexate [J]. Modern rheumatology, 2013, 23(2): 226-235.
EMERY P, DEODHAR A, RIGBY W F, et al. Efficacy and safety of different doses and retreatment of rituximab: a randomised, placebo-controlled trial in patients who are biological naive with active rheumatoid arthritis and an inadequate response to methotrexate (Study Evaluating Rituximab's Efficacy in MTX iNadequate rEsponders (SERENE)) [J]. Annals of the rheumatic diseases, 2010, 69(9): 1629-1635.
BEHRENS F, KOEHM M, ROSSMANITH T, et al. Rituximab plus leflunomide in rheumatoid arthritis: a randomized, placebo-controlled, investigator-initiated clinical trial (AMARA study) [J]. Rheumatology (Oxford, England), 2021, 60(11): 5318-5328.
STRAND V, BALBIR-GURMAN A, PAVELKA K, et al. Sustained benefit in rheumatoid arthritis following one course of rituximab: improvements in physical function over 2 years [J]. Rheumatology (Oxford, England), 2006, 45(12): 1505-1513.
COHEN S B, MORELAND L W, CUSH J J, et al. A multicentre, double blind, randomised, placebo-controlled trial of anakinra (Kineret), a recombinant interleukin 1 receptor antagonist, in patients with rheumatoid arthritis treated with background methotrexate [J]. Annals of the rheumatic diseases, 2004, 63(9): 1062-1068.
COHEN S, HURD E, CUSH J, et al. Treatment of rheumatoid arthritis with anakinra, a recombinant human interleukin-1 receptor antagonist, in combination with methotrexate: results of a twenty-four-week, multicenter, randomized, double-blind, placebo-controlled trial [J]. Arthritis and rheumatism, 2002, 46(3): 614-624.
CURTIS J R, MARIETTE X, GAUJOUX-VIALA C, et al. Long-term safety of certolizumab pegol in rheumatoid arthritis, axial spondyloarthritis, psoriatic arthritis, psoriasis and Crohn's disease: a pooled analysis of 11 317 patients across clinical trials [J]. RMD open, 2019, 5(1): e000942.
Downloads
Published
Issue
Section
How to Cite
